The original paper is in Mandarin and you can access it here (paywall): #Type2Diabetes #DiabetesResearch #Obesity #GLP1 #Semaglutide #Dorzagliatin #MetabolicHealth #HuaMedicine To view or add a comment, sign in A newly published peer-reviewed scientific paper from China adds to the growing body of evidence around the benefits that dorzagliatin (GKA) in combination with the popular semaglutide (GLP-1RA) delivers superior glycemic control, weight reduction, and islet cell function improvement when compared with semaglutide monotherapy in obese patients with Type 2 diabetes mellitus (T2DM), with a comparable safety profile
What is measured in these rats and mice (and occasionally in small groups of human volunteers) is often not a hard endpoint like muscle strength or weight loss, but surrogate biomarkers: molecules in the blood that have an indirect link to a hard endpoint
The half-life of injectable BPC-157 is estimated to be a few hours , though exact figures vary depending on the delivery method: Injectable BPC-157: Rapid absorption and clearance, typically 46 hours Oral capsules or sublingual forms: May have extended release times, but reduced bioavailability This means BPC-157 itself doesnt accumulate in your system over timebut the regenerative effects it stimulates (like collagen production and angiogenesis) can continue long after dosing ends
Peptide therapy involves using targeted amino-acid chains to signal specific functions in the body
Should you find any dissatisfaction with the product received, kindly contact us at 419-707-5450 or email our support team at [email protected]